Education
About Us
Working with TipRanks
Follow Us
MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
MBX Stock Chart & Stats
$30.42
-$0.30(-2.05%)
At close: 4:00 PM EST
$30.42
-$0.30(-2.05%)
Day’s Range― - ―
52-Week Range$4.81 - $34.83
Previous CloseN/A
Volume52.29K
Average Volume (3M)818.10K
Market Cap
$1.37B
Enterprise Value$207.43M
Total Cash (Recent Filing)$391.67M
Total Debt (Recent Filing)$623.00K
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Mar 23, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding44,902,300
10 Day Avg. Volume1,046,295
30 Day Avg. Volume818,103
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.39
Price to Sales (P/S)0.00
P/FCF Ratio-11.08
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$59.19Price Target Upside94.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCanvu exceeded high expectations with recent Phase II hypopara data, which gives conviction in Phase III success and its best-in-class profile supporting peak sales.
Innovative TechnologyMBX's prodrug technology appears perfectly suited to mitigate GI tox with GLP/GIPs, and 4291's infusion-like primate PK data lend confidence it exhibits an improved risk/benefit profile.
Market PotentialUpon launch, the differentiated QW dosing of canvu is expected to be preferred with new patients, expand the HP market, and drive conversion from Yorvi over time.
Bears Say
Clinical Trial RisksRisks include: 1) Clinical trial risk with lack of durability; 2) Unexpected safety concerns seen with drugs in ongoing clinical trials.
Financial And Regulatory RisksRisks include: 3) Cash need and dilution risk; 4) Increased regulatory, competitive, and pricing risk; and 5) If approved, competitive risk with lower than expected uptake of approved assets.
Safety ConcernsHypercalcemia was reported more frequently in higher dose groups during the titration period, which is an expected outcome when treating hypoparathyroidism patients with a PTH replacement therapy.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $34.83 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $1.37B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Mar 23, 2026 which is in 91 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.062.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.67.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 44,902,300 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went up 9.712%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.19 (94.58% Upside)
$59.19 (94.58% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 124.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.07%
12-Months-Change
Fundamentals
Return on Equity
-24.43%
Trailing 12-Months
Asset Growth
41.67%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX) is a biotechnology company focused on the discovery and development of peptide therapeutics to address unmet needs in endocrine disorders. The company leverages its proprietary platform to create novel therapies aimed at improving the lives of patients with complex hormonal conditions. MBX's core products are in various stages of clinical development, targeting specific endocrine diseases where current treatment options are limited or inadequate.
MBX Stock 12 Month Forecast
Average Price Target
$59.19
▲(94.58% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
Currently, No data available
---